


Supplementary Fig. S5 Modified-Downs and Black score of abstracts from conference proceedings (randomized controlled trials and observational studies): 11 studies¹⁻¹¹**References**

1. Markus R, et al. Results of functional testing and pharmacokinetics comparing ABP 215 to bevacizumab. *J Clin Oncol*. 2015;33(15 suppl):711.
2. Orlov SV, et al. Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients. *J Clin Oncol*. 2014;32(15 suppl):e13500.
3. Filon O, et al. Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting; 2015 29 May-2 June 2015; Chicago, IL.
4. Alexeev S, et al. Clinical comparability of BCD-020 to innovator rituximab in patients with indolent non-Hodgkin's lymphoma. *Haematologica*. 2014;99(suppl 1):144-5.
5. Florez A, et al. Clinical pharmacokinetic (PK) and safety (immunogenicity) of rituximab biosimilar RTX83 in combination with chemotherapy CHOP in patients with diffuse large B-cell lymphoma (DLBCL). *Blood*. 2014;124(21):5472.
6. Kim SJ, et al. Safety, pharmacokinetic/pharmacodynamic profiles and efficacy of SAIT101, a biosimilar of rituximab in patients with diffuse large B-cell lymphoma. *Haematologica*. 2012;97 (suppl 1):S317-S8.
7. Stenina MB, et al. Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients. *J Clin Oncol*. 2014;32(15 suppl):e11576.
8. Im Y, et al. Phase I/IIb clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6. *Breast*. 2013 2013;22(suppl 1):S108.
9. Im Y-H, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. *J Clin Oncol*. 2013;31(15 suppl):629.
10. Aliaga L, et al. Pharmacovigilance of anti CD 20 monoclonal antibody biosimilar at the Edgardo Rebagliati Martins Hospital-Peru. *Drug Saf*. 2013;36(9):925.
11. Menon H, et al. Pharmacokinetic and pharmacodynamic properties of a biosimilar rituximab (Reditux®) are identical to the innovator brand MabThera® – experience from a tertiary cancer centre in Western India. *Blood*. 2014;124(21):2246.